Hecht Beth 4

What Happened
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), sold 16,666 shares on July 1, 2026. The weighted-average sale price was $8.03 per share (range $7.92–$8.19), for total proceeds of approximately $133,860. The filing identifies the transactions as sales (S) and notes the trades were made under a Rule 10b5-1 trading plan adopted August 8, 2025.

Key Details

• Transaction date: July 1, 2026.
• Shares sold: 16,666; weighted avg price: $8.03; price range: $7.92–$8.19. (F2)
• Total proceeds: ~$133,860.
• Plan: Executed under a Rule 10b5-1 trading plan adopted Aug 8, 2025 (F1).
• Shares owned after transaction: not specified in the filing.
• Additional note: Filing references 1,288 shares acquired June 30, 2026 under the issuer’s ESPP (F3).
• Filing timeliness: Report filed July 2, 2026 for a July 1 transaction — within typical Form 4 deadlines (timely).

Context
Sales executed under a 10b5-1 plan are pre-scheduled and are often routine, so they do not necessarily indicate the insider’s current view of the company. This was a modestly sized sale (~$134k) by a senior officer; retail investors should consider this alongside other insider trades and company fundamentals rather than as a standalone signal.